NCT06164743View on ClinicalTrials.gov

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

May 15, 2024

Study Completion Date

May 15, 2024

Conditions
Inflammation
Interventions
DRUG

VVN461 Ophthalmic Solution 1.0%

Topical ocular drug

DRUG

VVN461 Ophthalmic Solution 0.5%

Topical ocular drug

DRUG

Vehicle

Topical ocular drug

Trial Locations (10)

32204

Levenson Eye Associates, Jacksonville

45242

Cincinnati Eye Institute, Cincinnati

63090

Comprehensive Eye Care, Ltd, Washington

77708

Houston Eye Associates, Houston

78731

Keystone Research, Austin

81501

ICON Eye Care, Grand Junction

89145

Center For Sight - Las Vegas, Las Vegas

90301

United Medical Research Institute, Inglewood

94954

North Bay Eye Associates, Petaluma

95670

Martel Eye Associates, Rancho Cordova

All Listed Sponsors
lead

VivaVision Biotech, Inc

INDUSTRY

NCT06164743 - Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery | Biotech Hunter | Biotech Hunter